Notably, one case achieved partial remission (PR) following combination therapy with crizotinib and nivolumab due to high PD-L1 expression in tumor tissues but later presented with recurrent pneumonitis resulting from both agents prompting a switch to alectinib  (29). The gene discussed is CD274; the disease is pneumonitis.